• Research, Science, and Trials

  FDA Approval Letter – Deadline is January 20th

  Posted by Christina Cordaro on January 13, 2021 at 8:26 am

  Thank you to everyone who signed, wrote a statement, and shared this effort. There has been 38,000 signatures and we are in our last week (deadline is January 20th)!

  Click here to read and sign the letter: http://www.curefa.org/advocacy

  *This letter requests Reata to submit a New Drug Application (NDA) on an urgent basis and FDA to exercise the flexibility granted by law and contained in FDA guidance in considering approval of an NDA for Omaveloxolone in FA based on the existing evidence from clinical trials.*

  qq

  Christina Cordaro replied 3 years, 3 months ago 1 Member · 0 Replies

  • clinical trial
  • FDA
  • FDA Approval
  • Reata Pharmaceuticals
• 0 Replies

Log In to Reply